BrightPath Biotherapeutics Co., Ltd.
Stock Price Chart
2026/10/09 19:27 UpdatedPrice Trend
2026/10/09 19:27 UpdatedPrice & Trading Details
2026/10/09 19:27 UpdatedPRICE
TRADING
Shareholder Composition
Updated 2026/10/01Financial Performance
2026/10/04 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥5M | ¥0M | ¥1M | ¥0M |
| Gross Profit | ¥3M | ¥0M | ¥1M | ¥0M |
| Operating Income | -¥1,467M | -¥1,155M | -¥1,161M | -¥1,295M |
| Pretax Income | -¥1,484M | -¥1,155M | -¥1,161M | -¥1,295M |
| Net Income | -¥1,486M | -¥1,168M | -¥1,151M | -¥1,305M |
| EPS | -¥24.90 | -¥18.21 | -¥14.12 | -¥11.70 |
| Operating Margin | -27,785.21% | -1,604,276.39% | -102,464.08% | -1,541,667.86% |
| Balance Sheet | ||||
| Total Assets | ¥1,701M | ¥1,230M | ¥1,121M | ¥2,605M |
| Total Equity | ¥1,568M | ¥979M | ¥925M | ¥2,368M |
| Total Liabilities | ¥134M | ¥251M | ¥196M | ¥236M |
| Cash | ¥1,531M | ¥1,057M | ¥810M | ¥2,156M |
| Interest-bearing Debt | ¥0M | ¥113M | ¥25M | ¥0M |
| Equity Ratio | 92.13% | 79.58% | 82.54% | 90.92% |
| D/E Ratio | 0.00 | 0.11 | 0.03 | 0.00 |
| Cash Flow | ||||
| Operating CF | -¥1,204M | -¥1,157M | -¥1,250M | -¥1,366M |
| Investing CF | -¥2M | -¥8M | -¥1M | -¥2M |
| Financing CF | ¥432M | ¥691M | ¥1,005M | ¥2,714M |
| Free CF | -¥1,206M | -¥1,165M | -¥1,252M | -¥1,366M |
| Efficiency | ||||
| ROE | -94.77% | -119.32% | -124.45% | -55.10% |
| ROA | -87.32% | -94.95% | -102.73% | -50.10% |
Latest IR Information
-
Notice of Completion of Payment for the Issue Price of the 21st Stock Acquisition Rights (with Exercise Price Adjustment Clause) Allocated to a Third Party
Today, BrightPath Biotherapeutics Co., Ltd. announced the completion of payment of the total issue price of 2,415,000 yen for the 21st stock acquisition rights allocated to a third party. The allottee is Phillip Capital Securities Japan Co., Ltd., the exercise...
Read more -
Supplementary Information for the 21st Issuance of Stock Acquisition Rights
BP issues stock acquisition rights as funding for the Phase I clinical trial of BP2202 in the United States. Potential issued shares: 34,500,000 shares; dilution: 24.84%; planned funds: 1,952 million yen. Exercise period: 2026/10/6–2027/10/6. Grants for exercise suspension, acquisition, and...
Read more -
Announcement on the Issuance of the 21st Stock Acquisition Right with Exercise Price Adjustment Provisions through Third-Party Allotment and the Conclusion of the Share Purchase Agreement for the Rights
Announces funding via third-party allotment using stock acquisition rights. 345,000 units, total 2,415,000 yen, potential shares 34,500,000 shares, initial exercise price 57 yen, adjusted to 97% of closing price on each adjustment date with rounding up; minimum 29 yen. Acquired...
Read more -
Notice on FDA IND Acceptance as of August 3, 2026
announces acceptance of FDA IND for BP2202. Enables US Phase I clinical trial initiation for iPSC-derived BCMA CAR-NKT cell therapy, aiming to administer the first patient within the year. Impact on fiscal year ending March 2027 is unknown, but advancement...
Read more -
Notice of IND Submission to the U.S. FDA Related to BP2202
Read more
Latest News (5 items)
Company Information
About
BrightPath Biotherapeutics Co., Ltd. engages in the development of cancer immunotherapy drugs in Japan. The company is developing BP2201, a product candidate in Phase I clinical trials to target cancer antigens in various types of cancer; BP2202, Phase I clinical trial to target cancer; and BP2301, a product candidate in Phase I clinical trials for the treatment of solid tumors sarcoma and gynecological cancers. In addition, its product candidates in preclinical trials include BP1200 that targets CD73; BP1202 that targets acute myeloid leukemia; BP1210, which suppresses T cell cytotoxicity; BP1212 to inhibit TIM-3 and CD39; BP1209 to target tumor-specific neo-antigens; and BP1223 to target blood cancers. The company was formerly known as GreenPeptide Co., Ltd. and changed its name to BrightPath Biotherapeutics Co., Ltd. in July 2017. The company was incorporated in 2003 and is headquartered in Kawasaki, Japan.
